Key clinical point: Aclidinium reduced COPD exacerbations and was similar to placebo in risk for major adverse cardiovascular events.
Major finding: Over a 3-year follow-up, 3.9% of COPD patients given oral aclidinium and 4.2% of those given a placebo experienced MACE.
Study details: The data were obtained from medical records of 2,537 adults with COPD randomized to aclidinium or placebo.
Disclosures: The study was supported at the outset by Forest Laboratories; it was later funded by AstraZeneca and Circassia. Dr. Wise disclosed personal fees from AstraZeneca, Contrafect, Pulmonx, Novartis, Mylan, Theravance, Roche, Spiration, Sunovion, Merck, Circassia, Pneuma, Verona, Bonti, Denali, Aradigm, Regeneron, Kiniksa, Syneos, and Propeller Health, as well as grants from Pearl Therapeutics and grants and personal fees from AstraZeneca/MedImmune, Boehringer Ingelheim, and GlaxoSmithKline.
Wise R et al. JAMA. 2019;321:1693-1701.